# Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome

> **NCT05597800** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Universita di Verona** · enrollment: 105 (estimated)

## Conditions studied

- NSCLC Stage IV
- HIV
- HBV
- HCV
- Long COVID

## Interventions

- **DRUG:** Nivolumab and Ipilimumab

## Key facts

- **NCT ID:** NCT05597800
- **Lead sponsor:** Universita di Verona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-03-30
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2022-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05597800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05597800, "Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05597800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*